New Drug Approved for Rare Neurological Disorder

Introducción

The FDA has recently approved zilganersen (Zanvastro) for the treatment of Alexander disease in both pediatric and adult patients. This approval marks a significant milestone as it is the first drug specifically designed to target this rare neurological condition.

Mecanismo de Acción

Zilganersen is an antisense oligonucleotide that directly addresses the buildup of glial fibrillary acidic protein (GFAP), a key factor that drives the progression of Alexander disease.

Importancia del Tratamiento

Dr. Emily Freilich from the FDA highlighted the importance of this approval, stating that until now, patients with Alexander disease had no approved treatment options, only supportive care as the disease advanced. The introduction of this drug is a landmark moment for affected families.

Características de la Enfermedad

Alexander disease is a progressive neurological disorder that affects fewer than one in a million people globally. It results from a mutation in the GFAP gene, which leads to excessive production and toxic accumulation of GFAP in astrocytes, potentially damaging neurons and myelin, and leading to serious complications.

Eficacia del Zilganersen

The drug has shown promise in reducing abnormal GFAP production before it can cause significant damage. In clinical trials involving 49 patients aged 2 years and older, it improved walking speed and gross motor skills in children compared to untreated individuals.

Administración y Efectos Secundarios

Zilganersen is administered quarterly through intrathecal injection. Common side effects include vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Aseptic meningitis has also been reported, and it is crucial for patients to keep their healthcare providers informed of any symptoms suggestive of meningitis.

Consulta de Información Completa

Healthcare professionals are encouraged to review the full prescribing information available to assist in treatment decisions. It is expected that zilganersen will be accessible in the United States in the coming weeks, as announced by Ionis Pharmaceuticals.

Disclaimer

This information is intended for educational purposes only and should not replace professional medical advice. Always consult a healthcare professional for treatment decisions.

Fuente: https://www.medpagetoday.com/neurology/generalneurology/122901